Read by QxMD icon Read

Diabetes Technology & Therapeutics

Julia Lawton, Maxine Blackburn, David Rankin, Janet M Allen, Fiona M Campbell, Lalantha Leelarathna, Martin Tauschmann, Hood Thabit, Malgorzata E Wilinska, Daniela Elleri, Roman Hovorka
OBJECTIVE: To explore individuals' experiences of daytime use of a day-and-night hybrid closed-loop system, their information and support needs, and their views about how future systems could be improved. RESEARCH DESIGN AND METHODS: Twenty-four adults, adolescents, and parents were interviewed before using a hybrid day-and-night closed-loop system and 3 months later, data were analyzed thematically. RESULTS: Participants praised the closed loop's ability to respond to high and low blood glucose in ways which extended beyond their own capabilities and to act as a safety net and mop up errors, such as when a mealtime bolus was forgotten or unplanned activity was undertaken...
February 5, 2019: Diabetes Technology & Therapeutics
Marianna Rachmiel, Yael Levy-Shraga, Noah Gruber, Orit Pinhas-Hamiel, Galia Barash, Dikla Pivko-Levy, Zohar Landau
BACKGROUND: The use of insulin pumps in pediatric patients with type 1 diabetes (T1D) has expanded; however, data comparing devices remain scarce. We compared glycemic control, technical difficulties, and quality of life (QOL) between pump devices of three companies. METHODS: This prospective observational trial is based on clinical data retrieved during 12 months of follow-up of pediatric patients who started pump therapy as part of their clinical care in four medical centers...
January 31, 2019: Diabetes Technology & Therapeutics
Stephan Siebel, Alfonso Galderisi, Neha S Patel, Lori R Carria, William V Tamborlane, Jennifer L Sherr
OBJECTIVE: We have shown that "euglycemic DKA" in patients with type 1 diabetes receiving a sodium-glucose cotransporter 2-inhibitor (SGLT2i) is due to normal increases in rates of ketogenesis but blunted increases in plasma glucose levels. In this analysis, we assessed whether rescue treatment of early ketoacidosis with insulin is altered by SGLT2i use. RESEARCH DESIGN AND METHODS: Participants received 0.2 U/kg of aspart insulin after two 6-h interruptions of basal insulin that increased beta-hydroxybutyrate (BHB) by 1...
January 28, 2019: Diabetes Technology & Therapeutics
John B Welsh, Peggy Gao, Mark Derdzinski, Sarah Puhr, Terri Kang Johnson, Tomas C Walker, Claudia Graham
BACKGROUND: Accuracy and feature sets of continuous glucose monitoring (CGM) systems may influence device utilization and outcomes. We compared clinical trial accuracy and real-world utilization and effectiveness of two different CGM systems. MATERIALS AND METHODS: Separately conducted accuracy studies of a fifth-generation and a sixth-generation CGM system involved 50 and 159 adults, respectively. For between-system performance comparisons, propensity score methods were utilized to balance cohort characteristics...
January 25, 2019: Diabetes Technology & Therapeutics
Brynn E Marks, Joseph I Wolfsdorf, Gretchen Waldman, Diane E Stafford, Katharine C Garvey
BACKGROUND: Recent data demonstrating a lack of improvement in average hemoglobin A1c levels despite the increased use of insulin pumps and continuous glucose monitors (CGMs) suggest that patients are not using these technologies optimally. Suboptimal provider understanding of these devices may be a contributing factor. METHODS: We sought to assess fellows' knowledge, attitudes, and practices regarding insulin pumps and CGMs using a mixed-methods survey. We polled 42 pediatric endocrinology fellows and 69 attending physicians in pediatric endocrinology using items on a five-point Likert scale...
January 25, 2019: Diabetes Technology & Therapeutics
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith, Beth A Olson, Satish K Garg
OBJECTIVE: To provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) in the United States and assessment of longitudinal changes in T1D management and clinical outcomes in the T1D Exchange registry. RESEARCH DESIGN AND METHODS: Data on diabetes management and outcomes from 22,697 registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with data collected in 2010-2012 for 25,529 registry participants. RESULTS: Mean HbA1c in 2016-2018 increased from 65 mmol/mol at the age of 5 years to 78 mmol/mol between ages 15 and 18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol beyond age 30...
January 18, 2019: Diabetes Technology & Therapeutics
Stacey M Anderson, Eyal Dassau, Dan Raghinaru, John Lum, Sue A Brown, Jordan E Pinsker, Mei Mei Church, Carol Levy, David Lam, Yogish C Kudva, Bruce Buckingham, Gregory P Forlenza, R Paul Wadwa, Lori Laffel, Francis J Doyle, J Hans DeVries, Eric Renard, Claudio Cobelli, Federico Boscari, Simone Del Favero, Boris P Kovatchev
BACKGROUND: Use of artificial pancreas (AP) requires seamless interaction of device components, such as continuous glucose monitor (CGM), insulin pump, and control algorithm. Mobile AP configurations also include a smartphone as computational hub and gateway to cloud applications (e.g., remote monitoring and data review and analysis). This International Diabetes Closed-Loop study was designed to demonstrate and evaluate the operation of the inControl AP using different CGMs and pump modalities without changes to the user interface, user experience, and underlying controller...
January 16, 2019: Diabetes Technology & Therapeutics
Gregory P Forlenza, Orit Pinhas-Hamiel, David R Liljenquist, Dorothy I Shulman, Timothy S Bailey, Bruce W Bode, Michael A Wood, Bruce A Buckingham, Kevin B Kaiserman, John Shin, Suiying Huang, Scott W Lee, Francine R Kaufman
OBJECTIVE: To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS: Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week baseline run-in phase in Manual Mode followed by a 3-month study phase with Auto Mode enabled. Sensor glucose (SG), glycated hemoglobin (HbA1c ), percentage of SG values across glucose ranges, and SG variability, during the run-in and study phases were compared...
December 26, 2018: Diabetes Technology & Therapeutics
Mary B Abraham, Grant J Smith, Jennifer A Nicholas, MSc Nursing, Janice M Fairchild, Bruce R King, Geoffrey R Ambler, Fergus J Cameron, Elizabeth A Davis, Timothy W Jones
BACKGROUND: The Predictive Low-Glucose Management (PLGM) system suspends basal insulin when hypoglycemia is predicted and reduces hypoglycemia. The aim of this analysis was to explore the characteristics of automated insulin suspension and sensor glucose (SG) responses following PLGM-initiated pump suspension. RESEARCH DESIGN AND METHODS: Children and adolescents with type 1 diabetes used the Medtronic MiniMed™ 640G pump as part of a randomized controlled trial...
December 26, 2018: Diabetes Technology & Therapeutics
Robert A Vigersky, Chantal McMahon
BACKGROUND: There has been recent recognition of the limitations of hemoglobin A1C (HbA1C) in describing both short- and long-term glycemic control. Continuous glucose monitoring (CGM) provides robust data about short-term glycemic control and provides metrics such as percent time-in-range (%TIR) that are now routinely reported to describe the change in glycemic control after an intervention in a clinical study or a change in therapy in a patient's care. Recent studies have shown that %TIR may have similar associations with diabetes microvascular complications as does HbA1C...
December 21, 2018: Diabetes Technology & Therapeutics
Sunil Deshpande, Jordan E Pinsker, Stamatina Zavitsanou, Dawei Shi, Randy Tompot, Mei Mei Church, Camille Andre, Francis J Doyle Iii, Eyal Dassau
BACKGROUND: There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms while running on an unlocked smartphone. METHODS: After algorithm verification, hazard and mitigation analysis, and complete system verification of iAPS, six adults with type 1 diabetes completed 1 week of sensor-augmented pump (SAP) use followed by 48 h of AP use with the iAPS, a Dexcom G5 CGM, and either a Tandem or Insulet insulin pump in an investigational device exemption study...
December 14, 2018: Diabetes Technology & Therapeutics
Jessica R Castle, Mikael Elander
No abstract text is available yet for this article.
February 2019: Diabetes Technology & Therapeutics
David Rodbard
No abstract text is available yet for this article.
February 2019: Diabetes Technology & Therapeutics
Irl B Hirsch
No abstract text is available yet for this article.
February 2019: Diabetes Technology & Therapeutics
Dominic Ehrmann, Lutz Heinemann, Guido Freckmann, Delia Waldenmaier, Gabriele Faber-Heinemann, Norbert Hermanns
BACKGROUND: While real-time continuous glucose monitoring (rtCGM) has proven its efficacy for glycemic control and avoidance of hypoglycemia, evidence on its effects on patient-reported outcomes is still inconclusive. This secondary analysis of the HypoDE study analyzed effect sizes of rtCGM on patient-reported outcomes and compared them with the effect sizes for glycemic outcomes. MATERIALS AND METHODS: The intervention group using rtCGM (n = 75) and the control group using self-monitored blood glucose measurements (n = 66) in the HypoDE study were compared...
February 2019: Diabetes Technology & Therapeutics
Werner Regittnig, Martina Urschitz, Barbara Lehki, Michael Wolf, Harald Kojzar, Julia K Mader, Martin Ellmerer, Thomas R Pieber
BACKGROUND: This study assessed subcutaneous absorption kinetics of rapid-acting insulin administered as a bolus using bolus delivery speeds commonly employed in commercially available insulin pumps (i.e., 2 and 40 s for delivering 1 insulin unit). MATERIALS AND METHODS: Twenty C-peptide-negative type 1 diabetic subjects were studied on two occasions, separated by at least 7 days, using the euglycemic clamp procedure. After an overnight fast, subjects were given, in random order, a subcutaneous insulin bolus (15 U of insulin lispro, Eli Lilly) either for 30 s using an Animas IR2020 pump (fast bolus delivery) or for 10 min using a Medtronic Minimed Paradigm 512 pump (slow bolus delivery)...
January 2019: Diabetes Technology & Therapeutics
Marie-Anne Burckhardt, Tarini Chetty, Grant J Smith, Peter Adolfsson, Martin de Bock, Timothy W Jones, Elizabeth A Davis
Diabetes care during exercise frequently requires interruptions to activity and adds extra challenges particularly for young individuals with type 1 diabetes (T1D). This study investigated the use of a carbohydrate (CHO) intake algorithm based on continuous glucose monitoring (CGM) trends during physical activity. Children with T1D diagnosed for >1 year, ages 8-12 years, with a glycated hemoglobin of <10% were recruited into a randomized crossover study. They attended two similar mornings of fun-based physical activity and adhered to either a CHO intake algorithm based on CGM trends (intervention) or to standard exercise guidelines (consumption of 0...
January 2019: Diabetes Technology & Therapeutics
Barbora Paldus, Melissa H Lee, Hannah M Jones, Sybil A McAuley, Jodie C Horsburgh, Kerryn L Roem, Glenn M Ward, Richard J MacIsaac, Neale Cohen, Peter G Colman, Alicia J Jenkins, David N O'Neal
Hybrid closed loop (HCL) insulin delivery with the Medtronic Minimed 670G system is effective and safe in people with type 1 diabetes (T1D). This study compared glucose control, closed loop (CL) exits, and alarm frequency with the standard HCL (s-HCL) versus enhanced HCL (e-HCL) Medtronic system. Pump-experienced T1D adults (n = 11; 9 female; mean [SD] age: 51 years [15 years]; HbA1c 7.5% [1.0%] or 58 mmol/mol [7.7 mmol/mol]) were assigned, in random order, s-HCL or e-HCL for 1 week each in a supervised live-in setting...
January 2019: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"